Verona Pharma plc (NASDAQ:VRNA – Get Rating) insider Kathleen A. Rickard sold 59,720 shares of the stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $0.54, for a total transaction of $32,248.80. Following the sale, the insider now directly owns 2,546,408 shares in the company, valued at approximately $1,375,060.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
VRNA stock opened at $4.21 on Wednesday. The company’s 50 day moving average price is $5.30 and its 200 day moving average price is $5.44. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.09 and a current ratio of 5.09. Verona Pharma plc has a fifty-two week low of $3.66 and a fifty-two week high of $8.69. The firm has a market capitalization of $254.15 million, a price-to-earnings ratio of -3.14 and a beta of 0.60.
A number of analysts recently weighed in on VRNA shares. Zacks Investment Research upgraded shares of Verona Pharma from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research note on Wednesday, April 6th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Verona Pharma in a research note on Tuesday, January 25th.
Verona Pharma Company Profile (Get Rating)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
- Get a free copy of the StockNews.com research report on Verona Pharma (VRNA)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.